How AI Sees What Radiologists Might Overlook
In medical imaging, subtle is the enemy. A tiny abnormality on a CT scan or mammogram can change everything. But when you're reviewing hundreds of images each week, fatigue, distraction, and sheer visual complexity can cause important details to slip through.
This is where AI becomes valuable—not by making final diagnoses, but by functioning as a persistent second observer.
Consider pancreatic cancer, one of the deadliest cancers precisely because it often hides. Early symptoms are either absent or vague. By the time it's discovered through traditional methods, the disease has usually advanced significantly. Researchers wanted to see if AI could spot warning signs earlier.
In a groundbreaking study published in Gut, researchers tested an AI model called REDMOD on routine CT scans of patients who were later diagnosed with pancreatic cancer. What makes this notable is that the AI was looking for patterns that were visually invisible to the human eye—patterns that existed in the images all along, but required computational analysis to reveal. REDMOD achieved 73.0% sensitivity and 81.1% specificity, with an average lead time of approximately 475 days before clinical diagnosis. That's roughly 16 months of additional warning time.
The clinical implication is significant: if a patient could have intervention started 16 months earlier, survival rates might improve substantially. But REDMOD doesn't diagnose cancer on its own. Instead, it flags something the radiologist should investigate further.
Breast cancer screening is evolving similarly. Modern mammography centers increasingly use AI-assisted reading systems. The workflow is straightforward: a radiologist performs the mammogram, takes the images, and then AI analyzes them in parallel. The system highlights areas that warrant closer attention—regions that might be suspicious or easily overlooked. The radiologist still makes the medical judgment. The AI simply increases the probability that nothing important gets missed.
From a patient's perspective, this often feels invisible. The experience of getting a mammogram doesn't change. What changes is what happens afterward—the review process becomes more rigorous, more standardized, and potentially more reliable.
Colonoscopy support works differently, but with the same underlying principle. During a colonoscopy, the gastroenterologist must identify polyps, some of which can become colorectal cancer. This requires sustained visual attention over 20, 30, or sometimes 40+ minutes. Even experienced physicians experience visual fatigue and can miss lesions. FDA-cleared systems like GI Genius analyze the live video feed during the procedure itself, alerting the physician to suspicious areas in real time. Again, the doctor retains authority. The AI is there to reduce human error in a high-stakes, real-time setting.
The Blood Test Revolution—And the Access Problem
This is where the promise meets a hard reality. A new diagnostic tool can be scientifically impressive and still be practically inaccessible to most patients.
Multi-cancer screening blood tests represent a genuinely different approach. Instead of looking for one cancer type, these tests analyze circulating tumor DNA (ctDNA) and other blood-based biomarkers to detect signals from multiple cancer types simultaneously. Companies like Grail have developed tests like Galleri that are clinically available right now. The test itself is simple—a blood draw, sent to a lab, results in days.
But consider the pathway a patient actually faces:
First: Does your doctor recommend it? Current U.S. screening guidelines already give patients and healthcare providers a framework. The CDC recommends colorectal cancer screening beginning at age 45. The U.S. Preventive Services Task Force recommends mammography every other year for women aged 40-74. These are the established standards. New AI tools fit within this framework, not outside it. A primary care physician must decide whether a multi-cancer blood test makes sense for a specific patient—considering age, risk factors, medical history, and the current state of clinical evidence.
Second: Is your insurance on board? This is where things get murky. Under the Affordable Care Act, many preventive services are covered without cost-sharing when you use in-network providers. Mammograms and colorectal cancer screening usually qualify. But newer multi-cancer blood tests? These occupy a gray zone. Some insurers consider them unproven. Others refuse to cover them entirely unless you fall into a high-risk category. A patient might receive a recommendation, only to discover the insurance company won't pay.
Third: What is the actual cost? If insurance refuses, the patient faces a decision: pay out of pocket or skip the test. Galleri, one of the most widely available multi-cancer screening tests, costs around $949 when not covered by insurance. Patients with HSA or FSA accounts can sometimes use these funds, but not everyone has them. For many people, nearly $1,000 for a screening test—even one that sounds impressive—is a barrier.
Some patients seeking AI-assisted breast imaging report additional charges. Susan G. Komen notes that some imaging centers charge patients $40-$100 for AI-assisted mammogram analysis, even though the mammogram itself may be covered as preventive care. The AI reading is often treated as an upgrade, subject to separate billing and patient responsibility.
What Patients Should Actually Consider
Before pursuing any AI-based cancer screening, ask yourself:
-
Is this recommended for someone my age and risk profile? Age and risk factors determine whether a test makes sense. A 35-year-old woman without breast cancer risk factors doesn't need mammography with or without AI assistance.
-
Is it preventive or diagnostic? Routine screening is treated differently from diagnostic testing. Preventive care has stronger insurance coverage guarantees.
-
Will my insurance cover it? Don't assume. Call your insurance company. Ask specifically about the test, the facility, and the provider. Get a written confirmation of coverage before proceeding.
-
What happens if the result is abnormal? This matters. A positive result on a cancer screening test usually means additional imaging, biopsies, or specialist visits. These follow-up procedures have their own costs, may not be covered the same way, and can create significant out-of-pocket expenses.
-
Am I prepared for a false positive? AI tools improve detection but are not perfect. False alarms happen. Unnecessary biopsies and anxiety follow. Is the benefit of early detection worth the psychological and financial burden of potential false alarms?
-
What is the actual benefit for me personally? A test might improve detection rates in a study population. But your individual benefit depends on your specific risk, the test's accuracy, and what you and your doctor plan to do with the information.
The Gap Between Innovation and Accessibility
The frustrating truth is this: AI cancer detection technology is advancing rapidly and becoming clinically available. But the systems that determine who gets access, who pays, and how much remain fragmented, confusing, and often inequitable.
A patient in a well-resourced academic medical center might have immediate access to cutting-edge AI screening tools with minimal out-of-pocket cost. A patient in a rural area or with limited insurance might never even hear about these options. A patient with good insurance might get coverage; another with worse coverage might not. None of this is about the technology's capability. It's about the healthcare system's structure.
The Realistic View of AI in Cancer Care
AI is genuinely useful in cancer detection. It can:
- Reduce human error in visually demanding tasks
- Increase consistency by applying the same analytical criteria to every case
- Highlight subtle patterns that humans might miss through fatigue or oversight
- Buy time by catching cancer earlier in its natural history
What AI cannot do—and should not try to do—is replace clinical judgment, eliminate the need for confirmatory testing, or substitute for established medical decision-making.
The real story of AI cancer screening is not just about what the technology can do. It's about whether patients can access it, whether they can afford it, whether insurance recognizes its value, and whether doctors have the information needed to recommend it appropriately.
The science is moving forward. Hospitals are adopting AI tools. Imaging centers and labs are integrating new systems. But healthcare policy, insurance reimbursement, and patient access have not caught up. Until they do, the promise of AI cancer detection will remain more accessible to some patients than to others.
The conversation with your doctor should be honest about both the potential and the practical limits: What does this test offer me specifically? What will it cost? What do we do with the results? And is it actually available to me, at a price I can afford?
That's the conversation that matters most.
Key Takeaways
- AI doesn't diagnose—it assists: AI tools are designed to support clinician judgment, not replace it
- Access varies dramatically: The technology exists, but availability depends on insurance, geography, and resources
- Ask practical questions: Cost, coverage, and follow-up implications matter as much as clinical accuracy
- Early detection isn't automatic benefit: Catching cancer earlier helps, but not in every case, and not without potential harms
- The healthcare system is catching up slowly: Innovation often outpaces policy and insurance coverage
Resources & References
-
Gut / BMJ — REDMOD Pancreatic Cancer AI Study
https://gut.bmj.com/content/early/2026/04/22/gutjnl-2025-337266 -
FDA — GI Genius (De Novo Summary)
https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN200055.pdf -
Galleri — Test Information & Cost
https://www.galleri.com/ -
HealthCare.gov — Preventive Health Services & Coverage
https://www.healthcare.gov/coverage/preventive-care-benefits/ -
CDC — Colorectal Cancer Screening Guidelines
https://www.cdc.gov/colorectal-cancer/screening/index.html -
U.S. Preventive Services Task Force — Breast Cancer Screening
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening -
Susan G. Komen — AI-Assisted Mammography
https://www.komen.org/blog/ai-assisted-mammogram/
Disclaimer: This article is for general informational purposes and should not be used as medical advice. Consult with a qualified healthcare provider to discuss screening options appropriate for your individual risk profile, costs, and coverage.
Comments
Post a Comment